Purchase this article with an account.
C. M. Favard, M. M. Mauget-Faÿsse, C. C. Français, G. G. Coscas; Anti VEGF Treatment of Classic Choroidal Newvessels in Age Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):344.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Is visual prognosis of the rare classic choroidal newvessels (CNV) improved by intravitreal (IVT) antiVEGF treatment ?
In this one year prospective study, we have analysed ETDRS visual acuity (VA), fluorescein angiography and OCT of classic CNVs, before and 4 to 6 weeks after each ranibizumab (6 eyes) or bevacizumab (6 eyes) IVT repeated after 2 initial sessions in case of persistence or recurrence.
Mean initial VA was 0,26 and final VA 0,20. Classic CNVs appeared occluded after first anti VEGF IVT in 3 eyes, after the second injection in 7 eyes and after third injection in 2 eyes. CNV recurrence occurred in 75% of cases after a mean evolution of 4 months. CNV scar appeared rapidly hyperpigmented in all cases with overlying retinal thinning on OCT and decreased vision of one or more ETDRS lines and central scotoma in 5 eyes. VA was increased in 5 eyes and stable in 2 eyes. In 2 cases a pseudomacular hole progressed to full thickness atrophic hole with a 1 and 4 lines VA decrease.
Anti VEGFs therefore improve visual prognosis of classic CNVs but an hyperpigmented scar and retraction of pseudomacular hole can induce VA decrease.
This PDF is available to Subscribers Only